News
Dentsply International 2Q profit rises 3 percent
July 29, 2010 8:45 am | by The Associated Press | CommentsDental products maker Dentsply International Inc. said Thursday its second-quarter profit rose 3 percent as an improved global economy boosted its sales.Dentsply said it earned $72.4 million, or 49 cents per share, over the three months that ended June 30. That's up from $70.2 million, or 47...
Covidien reports bumps in sales and profit
July 29, 2010 8:37 am | by Mass High Tech: The Journal of New England Technology | CommentsMedical device manufacturer Covidien plc has reported its third quarter results, including a 2 percent increase in net sales and net income of $364 million, compared with $281 million in the same quarter in 2009.
Suresh named chair of anesthesiology at Baylor College of Medicine
July 29, 2010 8:34 am | by Baylor College of Medicine | CommentsDr. Maya S. Suresh was named chair of the Department of Anesthesiology at Baylor College of Medicine by the college's board of trustees Wednesday. "Dr. Suresh has a clear vision for the future of this important discipline at Baylor College of Medicine," said Dr. Stephen Spann, senior vice...
Cubicin (daptomycin): Drug Safety Communication - Risk of Eosinophilic Pneumonia
July 29, 2010 8:30 am | by U.S. Food & Drug Administration | CommentsCases of serious, potentially fatal pneumonia associated with the IV antibacterial drug Cubicin.
Report: Sanofi may make $18.7B bid for Genzyme
July 29, 2010 6:36 am | by Mass High Tech: The Journal of New England Technology | CommentsFrench drug maker Sanofi-Aventis plans to make a formal bid to buy Genzyme Corp., for as much as $18.7 billion, Reuters news agency is reporting, quoting unnamed sources.
Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
July 29, 2010 6:35 am | by Bio-Medicine.Org | CommentsNEW YORK , July 29 /- Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint...
Shionogi Inc. Announces FDA Approval of CUVPOSAâ„¢ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
July 29, 2010 6:35 am | by Bio-Medicine.Org | CommentsFLORHAM PARK, N.J. , July 29 /- Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe...
Marina Biotech, Inc. Announces Upcoming Investor Conference Presentations
July 29, 2010 5:45 am | by The Associated Press | CommentsMarina Biotech, Inc. (NASDAQ: MRNAD), formerly known as MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that J. Michael French, Marina's President and Chief Executive Officer, will provide an overview of the Company and its progress in key...
Vitamin D deficiency linked to arterial stiffness in black teens
July 29, 2010 4:41 am | by EurekAlert | Comments(The Endocrine Society) Vitamin D deficiency is associated with arterial stiffness, a risk factor for heart disease and stroke, in black teens according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism. Black teens...
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
July 29, 2010 4:37 am | by Bio-Medicine.Org | CommentsSAN DIEGO , July 29 /- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks...
Free For All® Inc., MMM and PMC Assist Members with Pharmacy Discount
July 29, 2010 4:37 am | by Bio-Medicine.Org | CommentsMARLTON, N.J. , July 29 /- Free For All® Inc., MMM Healthcare, Inc. (MMM) and PMC Medicare Choice, Inc. today announced a plan to offer MMM/PMC members access to medications, lab testing and medical imaging at substantial rate reductions with the use of RxCut®Plus cards. The...
Winner Medical Launches Its First Online PurCotton(R) Store in China on Taobao.com
July 29, 2010 4:36 am | by Bio-Medicine.Org | CommentsSHENZHEN, China , July 29 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: WWIN ) ("Winner," or "the Company"), a leading manufacturer of medical dressings, medical disposables and non-woven PurCotton(R) materials for the medical and consumer products industries, announced today...
IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery
July 29, 2010 4:36 am | by Bio-Medicine.Org | CommentsMOUNTAIN VIEW, Calif. , July 29 /- IRIDEX Corporation (Nasdaq: IRIX ) today announced the receipt of an Issue Notification from the U.S. Patent and Trademark Office for U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent applies to a number of...
Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
July 29, 2010 4:36 am | by Bio-Medicine.Org | CommentsSAN DIEGO , July 29 /- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, will announce its second quarter ended June 30, 2010 financial results on Thursday, August 5, 2010 after the markets close. The announcement will be...
AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH®
July 29, 2010 4:36 am | by Bio-Medicine.Org | CommentsWOBURN, Mass.and VEDBAEK, Denmark , July 29 /- AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its Yeast Traffic Light® PNA FISH® test. The faster protocol reduces the PNA FISH turn-around time from the original 2.5...
